<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the diagnosis and staging of head and neck cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the diagnosis and staging of head and neck cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the diagnosis and staging of head and neck cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Colin S Poon, MD, PhD, FRCPC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kerstin M Stenson, MD, FACS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce E Brockstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marvin P Fried, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 08, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Head and neck cancers can arise in the oral cavity, pharynx, larynx, nasal cavity, paranasal sinuses, thyroid, and salivary glands and include a variety of histopathologic tumors.</p><p>An overview of the epidemiology, clinical presentation, diagnosis, and staging for head and neck cancer is presented here. More detailed discussions for specific primary tumor site are presented in the relevant site-specific topics. A general overview of treatment is also presented separately. (See  <a class="medical medical_review" href="/z/d/html/3380.html" rel="external">"Overview of treatment for head and neck cancer"</a>.)</p><p class="headingAnchor" id="H256481084"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>There are large geographic differences in the incidence and primary site of head and neck cancers. These likely reflect the prevalence of risk factors, such as tobacco and alcohol consumption, as well as ethnic and genetic differences among populations.</p><p>Although the highest rates of head and neck cancer are in older males, the incidence has been increasing in young nonsmokers, as human papillomavirus (HPV) plays an increasingly prominent role as an etiologic factor in the development of oropharyngeal head and neck cancer. Globally, head and neck cancer constituted 5.7 percent of cancer-related mortality [<a href="#rid1">1</a>]. Low- and middle-income countries are disproportionately burdened, as 67 percent of cases and 82 percent of deaths occurred in these countries.</p><p>Tobacco (smoked and smokeless) is the most important known risk factor for the development of head and neck cancer. There is some evidence for a genetic predisposition to the carcinogenic effects of tobacco. In addition, tobacco and alcohol consumption appear to have a synergistic effect. The repeated exposure of the mucosa of the upper aerodigestive tract to the carcinogenic effects of tobacco, alcohol, or both appears to cause multiple primary and secondary tumors in this "condemned mucosa," a phenomenon described as "field cancerization." </p><p>HPV infection is a causative agent for head and neck cancer. HPV associated head and neck cancers occur primarily in the oropharynx (tonsils and base of tongue), account for the younger age of patients with oropharyngeal squamous cell carcinoma, and define a subset of patients with improved treatment outcome. The use of HPV status in clinical decision-making remains investigational at this time, although there are multiple active deintensification trials currently in progress. The goal of these trials is to decrease the short- and long-term toxicity of treatment. Nonetheless treatment outside of a clinical trial remains the same as for patients without an HPV associated tumor. (See  <a class="medical medical_review" href="/z/d/html/3378.html" rel="external">"Epidemiology, staging, and clinical presentation of human papillomavirus associated head and neck cancer"</a>.)</p><p>Other head and neck cancer risk factors include betel nut chewing, radiation exposure, vitamin deficiencies, periodontal disease, immunosuppression, and other environmental and occupational exposures. (See  <a class="medical medical_review" href="/z/d/html/3390.html" rel="external">"Epidemiology and risk factors for head and neck cancer"</a> and  <a class="medical medical_review" href="/z/d/html/3405.html" rel="external">"Second primary malignancies in patients with head and neck cancers"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ANATOMIC SUBSITES</span><span class="headingEndMark"> — </span>Head and neck cancer encompasses a variety of malignancies, mostly squamous cell carcinoma, arising from a variety of sites. The head and neck region consists of several anatomic areas  (<a class="graphic graphic_figure graphicRef97306" href="/z/d/graphic/97306.html" rel="external">figure 1A</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral cavity </strong>– The oral cavity includes the mucosa of the lips (not the external, dry lip), the buccal mucosa, the anterior tongue, the floor of the mouth, the hard palate, and the upper and lower gingiva. The anterior border of the oral cavity is defined by the portion of the lip that contacts the opposed lip (wet mucosa). The posterior border is defined by the circumvallate papillae of the tongue, the anterior tonsillar pillars (palatoglossus muscles), and the posterior margin of the hard palate. The hard palate defines the superior boundary of the oral cavity. Inferiorly, the oral cavity is defined by the mylohyoid muscles. The lateral boundary of the oral cavity is defined by the buccomasseteric region (buccal mucosa of the cheeks) and the retromolar trigone (which is located behind the mandibular third molar).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharynx </strong>– The pharynx is divided into the nasopharynx, oropharynx, and hypopharynx. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nasopharynx </strong>– The nasopharynx forms the continuation of the nasal cavity. The boundary between the nasal cavity and nasopharynx is defined by the posterior choanae of the nasal cavity. The nasopharynx is defined superiorly by the basisphenoid and basiocciput (clivus) and inferiorly by the hard and soft palate. The prevertebral muscle and anterior margin of the cervical spine at C1 and C2 levels form the posterior margin of the nasopharynx. The posterolateral boundary of the nasopharynx includes several important structures. The lateral wall of the nasopharynx is elevated by the torus tubarius, a cartilaginous structure that constitutes the opening of the Eustachian tube. The Eustachian tube allows communication between the middle ear and the nasopharynx through a defect (sinus of Morgagni) of the pharyngobasilar fascia, which lines the nasopharynx. The sinus of Morgagni may allow nasopharyngeal cancer to gain access into the skull base. The fossa of Rosenmüller (lateral nasopharyngeal recess), a common site of nasopharyngeal cancer, is located posterior to the torus tubarius. The nasopharynx also includes the adenoids (nasopharyngeal tonsils), located in the midline roof of the nasopharynx.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oropharynx </strong>– The soft palate defines the boundary between the nasopharynx and oropharynx. The oropharynx is separated anteriorly from the oral cavity by the circumvallate papillae and the anterior tonsillar pillars. The palatine tonsils, posterior tonsillar pillars, tongue base (posterior one-third of the tongue), valleculae, soft palate and the posterior pharyngeal wall are structures of the oropharynx. Inferiorly, the oropharynx is defined by the hyoid and the pharyngoepiglottic folds. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypopharynx </strong>– The hypopharynx includes the pyriform sinuses, the posterior surface of the larynx (postcricoid area), and the inferior, posterior, and lateral pharyngeal walls.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Larynx </strong>– The larynx, which is divided into three anatomic regions: the supraglottic region, the glottic larynx (true vocal cords and mucosa of the anterior and posterior commissures), and the subglottic larynx, which extends to the inferior border of the cricoid cartilage.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nasal cavity and paranasal sinuses </strong>– The nasal cavity and the paranasal sinuses (maxillary, ethmoid, sphenoid, and frontal). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Salivary glands </strong>– The major (parotid, submandibular, and sublingual) and minor salivary glands. Minor salivary glands are found within the submucosa throughout the oral cavity, palate, paranasal sinuses, pharynx, larynx, trachea and bronchi, but are most concentrated in the buccal, labial, palatal, and lingual regions.</p><p></p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The clinical presentation of head and neck cancer varies widely depending upon the primary site and exposure to various risk factors. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Otalgia</strong> – Otalgia as a presenting symptom is significant. Cranial nerves 5, 7, 9, and 10 contribute afferents to the external and middle ear. Referred otalgia is considered a "red flag" in the evaluation of a patient with a possible head and neck malignancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nasopharyngeal carcinoma</strong> – The most frequent presenting complaint is a neck mass due to regional lymph node metastasis, which occurs in nearly 90 percent of patients. Symptoms due to the primary tumor may include hearing loss (associated with serous otitis media), tinnitus, nasal obstruction and pain, and its associated growth into adjacent anatomical structures, which can lead to muscle involvement and impaired function of cranial nerves II to VI. Adults with a unilateral effusion should have an examination of the nasopharynx.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral cavity tumors</strong> – Patients may present with mouth pain or nonhealing mouth ulcers, loosening of teeth, ill-fitting dentures, dysphagia, odynophagia, weight loss, bleeding, or referred otalgia. Up to 66 percent of patients with primary tongue lesions have cervical lymph node involvement, depending on T stage and depth of invasion, while the incidence is substantially lower in patients with hard palate cancers. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tongue cancer may grow as an infiltrative and/or exophytic lesion. The presenting symptom is often pain, with or without dysarthria. Dysarthria implies deep muscle invasion of advanced tumor stage. There may be a history of longstanding leukoplakia or erythroplakia. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lip cancer usually presents as an exophytic or ulcerative lesion of the lower lip, occasionally associated with bleeding or pain. Some patients complain of numbness of the skin of the chin due to involvement of the mental nerve. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oropharyngeal tumors</strong> – Presenting complaints can include dysphagia, pain (odynophagia, otalgia), obstructive sleep apnea or snoring, bleeding, or a neck mass  (<a class="graphic graphic_picture graphicRef120046" href="/z/d/graphic/120046.html" rel="external">picture 1</a>). </p><p></p><p class="bulletIndent1">Patients with human papillomavirus (HPV) positive oropharyngeal cancers often present with neck masses  (<a class="graphic graphic_table graphicRef129474" href="/z/d/graphic/129474.html" rel="external">table 1</a>). Many of these patients do not have other clinical complaints, including the classic symptoms of odynophagia and otalgia. Neck mass, which is often cystic, may be the only clinical complaint. These cystic neck masses are often mistaken for branchial cleft cyst carcinomas. In reality, branchial cleft cyst carcinoma is exceptionally rare and its diagnosis should be one of exclusion rather than presumption [<a href="#rid2">2</a>]. For adult patients presenting with cystic neck mass, metastatic cystic squamous cell carcinoma associated with HPV needs to be strongly considered and excluded. (See  <a class="medical medical_review" href="/z/d/html/3378.html" rel="external">"Epidemiology, staging, and clinical presentation of human papillomavirus associated head and neck cancer"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypopharyngeal tumors</strong> <em>– </em>Patients with these tumors often remain asymptomatic for a longer period and are therefore more likely to be seen in the later stages of the disease. Dysphagia, odynophagia, otalgia, weight loss, hemoptysis, dyspnea, and neck mass are common presenting symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laryngeal cancer</strong> – The symptoms associated with cancer of the larynx depend upon location. Persistent hoarseness may be the initial complaint in glottic cancers; later symptoms may include dysphagia, referred otalgia, chronic cough, hemoptysis, and stridor. Supraglottic cancers are often discovered later and may present with airway obstruction or palpable metastatic lymph nodes. Primary subglottic tumors are rare. Affected patients typically present with stridor or complaints of dyspnea on exertion. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sinus tumors</strong> – Common presenting symptoms of sinus tumors include epistaxis and unilateral nasal obstruction. Facial and/or head pain may be seen in later stages, due to pressure or tumor infiltration into nerves or periosteum. </p><p></p><p class="headingAnchor" id="H4"><span class="h1">PATHOLOGY</span></p><p class="headingAnchor" id="H1919282106"><span class="h2">Histology</span><span class="headingEndMark"> — </span>Squamous cell carcinomas account for 90 to 95 percent of the lesions in the oral cavity and larynx. They can be categorized as well differentiated (greater than 75 percent keratinization), moderately differentiated (25 to 75 percent keratinization), and poorly differentiated (less than 25 percent keratinization) tumors. Less common histologies include verrucous carcinoma (a variant of squamous cell carcinoma), adenocarcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinomas. (See  <a class="medical medical_review" href="/z/d/html/3375.html" rel="external">"Pathology of head and neck neoplasms", section on 'Squamous cell carcinoma'</a>.) </p><p>Squamous cell carcinoma of the head and neck often develops through a series of changes from premalignant entities due to carcinogen exposure. (See  <a class="medical medical_review" href="/z/d/html/3375.html" rel="external">"Pathology of head and neck neoplasms", section on 'Squamous cell carcinoma precursors'</a>.)</p><p>Clinical signs include leukoplakia and erythroplakia: </p><p class="bulletIndent1"><span class="glyph">●</span>Leukoplakia is characterized by hyperparakeratosis and is usually associated with underlying epithelial hyperplasia. In the absence of underlying dysplastic changes, the probability of malignant change is less than 5 percent [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erythroplakia is characterized by red superficial patches adjacent to normal mucosa. It is commonly associated with epithelial dysplasia and is associated with carcinoma in situ or invasive tumor in up to 40 percent of cases [<a href="#rid3">3</a>].</p><p></p><p>Histopathologic findings include dysplasia: </p><p class="bulletIndent1"><span class="glyph">●</span>Dysplasia is defined histopathologically by the presence of mitoses and prominent nucleoli. Involvement of the entire mucosal thickness is usually referred to as carcinoma in situ. Dysplasia is associated with progression to invasive cancer in 15 to 30 percent of cases.</p><p></p><p class="headingAnchor" id="H2923442336"><span class="h2">HPV testing</span><span class="headingEndMark"> — </span>Human papillomavirus (HPV) infection is a causative agent for oropharyngeal squamous cell carcinoma, and HPV tumor status is incorporated into the staging system of these tumors. We agree with the approach to HPV evaluation proposed by the College of American Pathologists (CAP) and endorsed by the American Society of Clinical Oncology (ASCO) [<a href="#rid4">4,5</a>]. HPV tumor status should be determined for all cases of newly diagnosed oropharyngeal squamous cell carcinoma. HPV tumor status is not appropriate for the routine evaluation of nonsquamous carcinoma of the oropharynx, or nonoropharyngeal squamous cell carcinoma of the head and neck. It may be useful in select cases of oropharyngeal cancer with uncertain histology.</p><p>The preferred method for determining HPV tumor status is surrogate marker p16 immunohistochemistry [<a href="#rid4">4,5</a>]. Overexpression of this surrogate marker is strongly associated with transcriptionally active high-risk HPV. The threshold for positivity is at least 70 percent nuclear and cytoplasmic expression with at least moderate to strong intensity. However, there can be false-positive and false-negative results; HPV in situ hybridization or polymerase chain reaction can be used to clarify HPV status when the clinical scenario and p16 results are discordant.</p><p>Additional information about HPV associated head and neck cancer is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3378.html" rel="external">"Epidemiology, staging, and clinical presentation of human papillomavirus associated head and neck cancer"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">TNM STAGING SYSTEM</span><span class="headingEndMark"> — </span>The eighth edition of the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) Tumor, Node, Metastasis (TNM) staging system is used to classify cancers of the head and neck [<a href="#rid6">6</a>]. The T classifications indicate the extent of the primary tumor and are site specific; there is considerable overlap in the cervical N classifications.</p><p>TNM staging varies depending upon the primary tumor site:</p><p class="bulletIndent1"><span class="glyph">●</span>Oral cavity  (<a class="graphic graphic_table graphicRef110767" href="/z/d/graphic/110767.html" rel="external">table 2</a>) (see  <a class="medical medical_review" href="/z/d/html/3407.html" rel="external">"Treatment of stage I and II (early) head and neck cancer: The oral cavity", section on 'Clinical presentation and diagnosis'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nasopharynx  (<a class="graphic graphic_table graphicRef110658" href="/z/d/graphic/110658.html" rel="external">table 3</a>) (see  <a class="medical medical_review" href="/z/d/html/3372.html" rel="external">"Treatment of early and locoregionally advanced nasopharyngeal carcinoma", section on 'Histology'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oropharynx  (<a class="graphic graphic_table graphicRef110659 graphicRef110628" href="/z/d/graphic/110659.html" rel="external">table 4A-B</a> and <a class="graphic graphic_table graphicRef110640 graphicRef110641" href="/z/d/graphic/110640.html" rel="external">table 5A-B</a>) (see  <a class="medical medical_review" href="/z/d/html/3399.html" rel="external">"Treatment of early (stage I and II) head and neck cancer: The oropharynx", section on 'Staging'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypopharynx  (<a class="graphic graphic_table graphicRef110661 graphicRef110631" href="/z/d/graphic/110661.html" rel="external">table 6A-B</a>) (see  <a class="medical medical_review" href="/z/d/html/3397.html" rel="external">"Treatment of early (stage I and II) head and neck cancer: The hypopharynx", section on 'Anatomy and staging'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Larynx  (<a class="graphic graphic_table graphicRef110769" href="/z/d/graphic/110769.html" rel="external">table 7</a>) (see  <a class="medical medical_review" href="/z/d/html/3388.html" rel="external">"Treatment of early (stage I and II) head and neck cancer: The larynx", section on 'Staging and anatomy'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nasal cavity and paranasal sinuses  (<a class="graphic graphic_table graphicRef110768" href="/z/d/graphic/110768.html" rel="external">table 8</a>) (see  <a class="medical medical_review" href="/z/d/html/3403.html" rel="external">"Cancer of the nasal vestibule", section on 'Staging'</a> and  <a class="medical medical_review" href="/z/d/html/3401.html" rel="external">"Paranasal sinus cancer", section on 'Diagnosis and staging'</a> and  <a class="medical medical_review" href="/z/d/html/16861.html" rel="external">"Tumors of the nasal cavity"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Salivary glands  (<a class="graphic graphic_table graphicRef110657 graphicRef110617" href="/z/d/graphic/110657.html" rel="external">table 9A-B</a>) (see  <a class="medical medical_review" href="/z/d/html/3400.html" rel="external">"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging", section on 'Staging'</a>)</p><p></p><p class="headingAnchor" id="H6"><span class="h1">DIAGNOSIS AND STAGING EVALUATION</span></p><p class="headingAnchor" id="H6093579"><span class="h2">Initial evaluation</span><span class="headingEndMark"> — </span>The initial assessment of the primary tumor is based upon a thorough history and combination of inspection, palpation, indirect mirror examination, or direct flexible laryngoscopy. Physical examination should include careful assessment of the nasal cavity and oral cavity with visual examination and/or palpation of mucous membranes, the floor of the mouth, the anterior two-thirds of the tongue, tonsillar fossae and tongue base (best seen on mirror examination or flexible laryngoscopy), palate, buccal and gingival mucosa, and posterior pharyngeal wall. </p><p>External auditory canal examination and anterior rhinoscopy should be undertaken.</p><p>For patients with non-laryngeal lesions but a strong alcohol or smoking history, flexible laryngoscopy is commonly undertaken to visualize potential other lesions and to document vocal cord mobility.</p><p>A metastatic work-up with appropriate imaging is recommended for all newly-diagnosed head and neck cancer patients, with particular attention to regional lymph node spread. For those with locoregionally advanced tumors, distant metastatic imaging, with attention to the lungs, is often performed. Patients with severe dysplasia or carcinoma in situ who have a strong smoking, alcohol, or family history of cancer may also benefit from a more extensive work-up for metastases or a second primary including a screening chest computed tomography (CT). Use of clinical judgement is important. (See  <a class="medical medical_review" href="/z/d/html/7566.html" rel="external">"Screening for lung cancer"</a>.)</p><p>Visualization of lesions outside the mouth is best accomplished by mirror examination and/or the use of a flexible fiberoptic endoscope with the goal of examining all of the mucosa in the nasopharynx oropharynx, hypopharynx, and larynx. Aside from mucosal irregularities, other abnormalities that should be specifically searched for are impairment of vocal cord mobility, pooling of secretions, anatomic asymmetries, and bleeding. The appropriate nodal drainage areas are examined by careful palpation of the neck. Examination of the neck for pathologic adenopathy or other masses is best done according to neck levels. The parotid glands are also palpated for abnormalities  (<a class="graphic graphic_figure graphicRef54099" href="/z/d/graphic/54099.html" rel="external">figure 2</a>).</p><p>Due to improved radiologic and in-office biopsy techniques, an examination under anesthesia (EUA) is most often performed only to obtain a tissue diagnosis, for surgical (eg, robotic) planning, and to search for carcinoma of unknown primary [<a href="#rid7">7,8</a>]. This examination is particularly useful for patients with laryngeal and hypopharyngeal malignancies. (See  <a class="medical medical_review" href="/z/d/html/3388.html" rel="external">"Treatment of early (stage I and II) head and neck cancer: The larynx"</a> and  <a class="medical medical_review" href="/z/d/html/3397.html" rel="external">"Treatment of early (stage I and II) head and neck cancer: The hypopharynx"</a> and  <a class="medical medical_review" href="/z/d/html/3402.html" rel="external">"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx"</a>.)</p><p>Symptom-directed panendoscopy (laryngoscopy, bronchoscopy, and esophagoscopy) reveals a 2.4 to 4.5 percent incidence of second primary tumors of the upper aerodigestive tract but not of the lower airways [<a href="#rid9">9-11</a>]. Other authors have found that screening panendoscopy revealed second primary cancers only in patients with a current or past smoking history [<a href="#rid12">12</a>]. There is evidence that positron emission tomography (PET) may complement or replace panendoscopy in detecting synchronous primary cancers [<a href="#rid13">13</a>], although some studies have shown there is still a risk of false negatives (9 in 589 patients in one study). In general, patients with a history of heavy alcohol or tobacco use should undergo a work-up for second primary tumors with PET or panendoscopy as part of their operative staging for characterization of the primary tumor or to look for distant disease in early stage disease. Operative staging and/or panendoscopy may find synchronous primaries that are too small to be identified with PET, while PET may identify lower aerodigestive tract tumors not seen with panendoscopy. In a retrospective study of 190 patients with unknown primary sites, it was found that panendoscopy with directed biopsies and tonsillectomy complemented PET scan studies. The authors maintain that panendoscopy and biopsies has a significant role in evaluation in patients with unknown primary sites, especially in patients with negative PET scans [<a href="#rid14">14</a>]. Although the incidence of second or synchronous primary tumor is low, the impact on treatment for the individual patient is significant. Those with human papillomavirus (HPV) positive tumors without other known risk factors are not as likely to benefit from panendoscopy.</p><p>Imaging studies may augment the physical exam and evaluation of squamous cell carcinoma of the head and neck, particularly for assessing the degree of local invasion, involvement of regional lymph nodes, and presence of distant metastases or second primary malignancies. The most common metastatic sites are the lungs, liver, and bone, while the most common sites of second primary malignancies are the head and neck, followed by the lungs and esophagus. Ideally, imaging should take place prior to biopsy, which may distort anatomy and create a false-positive finding on PET scanning. (See <a class="local">'Imaging studies'</a> below and <a class="local">'Evaluation for distant metastases'</a> below.)</p><p class="headingAnchor" id="H7"><span class="h2">Fine needle aspiration biopsy</span><span class="headingEndMark"> — </span>Fine needle aspiration (FNA) biopsy is frequently used to make an initial tissue diagnosis of a head and neck cancer when a patient presents with a neck mass (metastatic cervical lymph node) without an obvious primary mucosal/upper aerodigestive tract site. This technique has high sensitivity and specificity and a diagnostic accuracy that ranges from 89 to 98 percent [<a href="#rid15">15-17</a>]. Nondiagnostic aspirations occur in 5 to 16 percent of cases, most commonly in cystic neck masses, as is common in the presentation of patients with HPV associated oropharyngeal cancers. If an initial FNA is negative from a suspicious neck node, repeat FNA may be considered before doing an excisional biopsy. (See  <a class="medical medical_review" href="/z/d/html/14251.html" rel="external">"Head and neck squamous cell carcinoma of unknown primary"</a>.) </p><p>FNA biopsy of a suspected involved lymph node in the setting of an established primary tumor may provide relevant information when clinical and imaging evaluation of neck lymph nodes is equivocal and a positive or negative finding would change the clinical treatment approach (eg, radiation therapy field or dose, or the use of concurrent chemoradiotherapy versus radiation therapy alone). Several studies have compared ultrasound plus ultrasound-guided FNA biopsy with neck CT; the procedures were comparable in terms of overall accuracy (88 and 85 percent in one series compared with 69 percent by palpation) [<a href="#rid18">18,19</a>], while others noted better results with FNA [<a href="#rid20">20,21</a>]. In one report of 86 patients with clinically node-negative (N0) necks, ultrasound with FNA-detected malignancy in five who did not fulfill radiologic criteria for malignancy by CT scan [<a href="#rid22">22</a>]. Conversely, several enlarged nodes on CT scan were negative by cytology (ie, they potentially represented a false-positive finding). PET may also have a role in the evaluation of cervical lymph nodes, although PET scan will not identify occult/microscopic disease. (See <a class="local">'PET and integrated PET/CT'</a> below.)</p><p class="headingAnchor" id="H1571847746"><span class="h2">Sentinel lymph node biopsy</span><span class="headingEndMark"> — </span>Sentinel lymph node biopsy (SLNB) is another promising strategy for increasing the accuracy of overall staging of head and neck cancer [<a href="#rid23">23-26</a>]. Further details on the use of SLNB in patients with early-stage oral cavity tumors (including technique, approach, and subsequent management) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3407.html" rel="external">"Treatment of stage I and II (early) head and neck cancer: The oral cavity", section on 'Sentinel lymph node biopsy'</a>.)</p><p>When performed at centers with clinical expertise in this approach, SLNB is a reliable and reproducible method for staging the clinically and radiologically N0 neck in patients with early-stage oral cavity cancer. SLNB can also be used to determine the best treatment for contralateral N0 neck in patients with midline malignancies and node positive ipsilateral disease. SLNB is technically feasible, reliable (high sensitivity if the three highest intensity nodes are sampled), oncologically safe, and associated with less morbidity than elective neck dissection. This technique is becoming more widely used in the United States and has been integrated into the National Comprehensive Cancer Network (NCCN) treatment guidelines [<a href="#rid27">27,28</a>]. </p><p class="headingAnchor" id="H8"><span class="h2">Imaging studies</span><span class="headingEndMark"> — </span>Imaging studies (CT, magnetic resonance imaging [MRI], PET, and integrated PET/CT) are important for assessing the degree of local infiltration, involvement of regional lymph nodes, and presence of distant metastases or second primary tumors. </p><p>There is increased awareness of patient exposure to radiation dose during medical imaging. Although the overall risk of radiation-induced malignancy is small, it is non-negligible when population-based screening is considered. Previous literature estimates that approximately 1.5 to 2 percent of all cancers in the United States may be attributable to radiation from CT studies [<a href="#rid29">29</a>]. The risk estimation of CT radiation to individual patients is a difficult subject, as evolving CT technology continues to help reduce radiation dose [<a href="#rid30">30</a>] and the risk of induced cancer decreases with patient age. The potential risk versus the anticipated benefits of CT scans must be taken into account [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H9"><span class="h3">CT scan</span><span class="headingEndMark"> — </span>CT can identify tumors of the head and neck based upon either anatomic distortion or specific tumor enhancement  (<a class="graphic graphic_diagnosticimage graphicRef91084" href="/z/d/graphic/91084.html" rel="external">image 1</a>). In general, tumors enhance more than normal head and neck structures except for mucosa, extraocular muscles, and blood vessels [<a href="#rid32">32</a>]. Compared with MRI, CT provides greater spatial resolution, can be performed with faster acquisition times (thereby virtually eliminating motion artifact), and is better at evaluating bone destruction. CT technology that reduces metallic artifact is also being incorporated into routine clinical practice [<a href="#rid33">33</a>].</p><p>Modern multidetector CT technology allows scanning to be performed with slice thickness less than 1 mm. Slice thickness of 3 mm is generally optimal, while slice thickness greater than 5 mm does not offer sufficient spatial resolution. Images should be reconstructed and viewed in both soft tissue and bone windows. Dental amalgam can create severe beam hardening image artifacts that obscure image details in the scan plane. This problem can be remedied by rescanning the obscured area with angulated gantry.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary site</strong> – For cancers of the oral cavity, contrast-enhanced CT can help determine the extent of tumor infiltration into deep tongue musculature and whether or not the mandible is involved. The "puffed cheek" technique improves evaluation of lesions of the oral cavity. This technique requires patients to self-insufflate their oral cavity with air by puffing out their cheek [<a href="#rid34">34</a>]. For other head and neck cancers, CT is particularly useful in upstaging cancers that have deeper local invasion or infiltration into adjacent structures that is difficult to detect on physical examination. CT can provide information on invasion of the pre-epiglottic space, laryngeal cartilage, paraglottic space and subglottic extension, and can evaluate retropharyngeal, parapharyngeal, upper mediastinal, and paratracheal nodes. In addition, bone and cartilage invasion, a criterion for stage T4 disease, can be more readily detected.</p><p></p><p class="bulletIndent1">Distinction of cartilage invasion from non-ossified cartilage can be a difficult task for conventional CT. The new technology of dual energy and multispectral CT has demonstrated improved accuracy for assessing cartilage invasion compared with conventional CT [<a href="#rid35">35</a>]. Preliminary results have demonstrated an increase of specificity for evaluation of thyroid cartilage invasion from 70 to 96 percent, with no compromise of sensitivity (86 versus 86 percent) [<a href="#rid35">35,36</a>]. In general, the advantage of improved tissue characterization offered by dual-energy and spectral CT may enhance the accuracy of CT for evaluation of tumor extent and staging [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1">In one review of 81 patients with head and neck cancer, CT resulted in a change in assigned clinical stage in 54 percent of cases [<a href="#rid38">38</a>]. This was most likely to occur with hypopharyngeal tumors and least likely with glottic laryngeal tumors (90 and 16 percent, respectively). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regional nodes</strong> – Imaging by CT or MRI is complementary to the clinical examination for the staging of the neck lymph nodes. CT evaluation of regional lymph nodes primarily relies upon size criteria as well as the appearance of lymph nodes to differentiate involved from uninvolved lymph nodes. The use of size criteria alone results in frequent false-positive and false-negative assessment of regional nodes. CT is also highly sensitive for detection of extracapsular spread of tumor.</p><p></p><p class="bulletIndent1">Pathologic lymphadenopathy is usually defined radiologically as a node greater than 10 to 11 mm in minimal axial diameter or one that contains central necrosis [<a href="#rid39">39-42</a>]. The choice of how a lymph node is measured is often controversial and reflects a tradeoff between sensitivity and specificity. In general, size criteria based on measurement of minimal axial diameter are considered the most accurate and effective [<a href="#rid43">43,44</a>], and probably the most reproducible [<a href="#rid45">45</a>]. Other features that suggest pathological lymph nodes include rounded shape, loss of normal fatty hilum, increased or heterogeneous contrast enhancement, lymph node clustering, and sentinel lymph node location [<a href="#rid46">46</a>]. In one study, data from 47 consecutive patients with head and neck cancer (total of 53 neck dissections) were combined with findings from a 15-year MEDLINE review of the English-language literature to compare physical examination with CT scan [<a href="#rid47">47</a>]. CT was superior to physical examination in terms of sensitivity (83 versus 74 percent), specificity (83 versus 81 percent), accuracy (83 versus 77 percent), and detection of pathologic cervical adenopathy (91 versus 75 percent).</p><p></p><p class="bulletIndent1">Although CT is superior to physical examination, the use of size criteria and the presence of central necrosis are limitations that prevent detection of borderline-sized nodes, nonnecrotic nodes, or extracapsular spread confined within the radiologically-defined margin of nodes. These cannot be differentiated by CT from reactive or normal nodes [<a href="#rid39">39</a>]. This is an important issue since microscopic or occult nodal adenopathy is not unusual in head and neck cancer.</p><p></p><p class="bulletIndent1">In one series of 957 lymph nodes from patients with head and neck cancer, 102 (11 percent) harbored malignant cells [<a href="#rid48">48</a>]. The following findings were noted in terms of nodes that would not be called malignant by CT:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sixty-seven percent of tumor-containing nodes were 10 mm or smaller.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Twenty percent of malignant nodes had extracapsular spread; almost one-third of these nodes were 10 mm or smaller and some were less than 5 mm.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Central necrosis was found primarily in nodes larger than 20 mm, suggesting that it is a late event in metastatic adenopathy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Extracapsular spread of nodal metastasis is an important prognostic factor that should be assessed on imaging. Imaging findings that suggest extracapsular spread of nodal metastasis include irregular border of the lymph node, infiltration of adjacent fat planes, and loss of cleavage plane with adjacent anatomical structures.</p><p></p><p class="headingAnchor" id="H10"><span class="h3">Magnetic resonance imaging</span><span class="headingEndMark"> — </span>MRI provides superior soft tissue definition compared with CT [<a href="#rid49">49</a>] and can often provide information that is complementary to CT. For example, MRI can provide more accurate definition of tumors of the tongue and is more sensitive for superficial tumors. MRI is also better than CT for discriminating tumor from mucus and in detecting bone marrow invasion [<a href="#rid50">50</a>]. For this reason, MRI can be useful for evaluation of cartilage invasion, particularly for non-ossified cartilage that can pose difficulty for CT. On the other hand, CT scanning is better than MRI for detection of bone cortex invasion since MRI shows no bony detail. The availability of dual energy and multispectral CT, however, may decrease the advantage of MRI in cartilage evaluation [<a href="#rid35">35,36,51</a>].</p><p>MRI is superior to CT for evaluation of perineural spread, skull base invasion, and intracranial extension of head and neck cancer. MRI may also provide additional benefits compared with CT in the evaluation of the base of tongue and parotid glands. MRI scan is the imaging modality recommended by the NCCN guidelines to evaluate skull base erosion for nasopharyngeal cancer [<a href="#rid52">52</a>].</p><p>The most important imaging sequences for head and neck imaging include noncontrast-enhanced T1-weighted images, contrast-enhanced T1-weighted images with fat suppression, and fat-suppressed fluid-sensitive sequences, such as T2-weighted images with fat suppression or short-tau inversion recovery (STIR) images. Images in axial and coronal plane are the most useful. For general purpose, slice thickness should be no more than 5 mm. Some applications, such as evaluation of skull base and perineural spread, may require thinner slice thickness, typically around 3 mm.</p><p>In most studies, CT scanning outperforms MRI for the detection of pathologic nodal metastases. The reported sensitivity of MRI is as low as 57 to 67 percent. However, neither test reliably detects clinically occult regional node involvement.</p><p class="headingAnchor" id="H11"><span class="h3">PET and integrated PET/CT</span><span class="headingEndMark"> — </span>With PET, injected positron-emitting radionuclides, such as fluorine-18, are taken up by metabolically or functionally active tissues. PET images are created by detecting these emissions by an array of detectors and then using reconstruction techniques to create a three dimensional image. The most commonly used agent is fluorodeoxyglucose (FDG), which is taken up into cells in different concentrations depending on the relative metabolism of different tissues. It is fairly specific for tumors because metabolic rates are very high in many tumors.</p><p>PET has intrinsically lower spatial resolution than other imaging modalities. In addition, it may be difficult to localize the anatomic location of the FDG uptake. These issues are addressed with integrated PET/CT imaging, in which PET and CT are performed sequentially during the same imaging session on a hybrid PET/CT scanner. The images are then coregistered using fusion software, enabling the physiologic data obtained on PET to be localized according to the anatomic CT images.</p><p>Historically, CT images obtained from integrated PET/CT scanners had lower spatial resolution compared with dedicated CT scanners. This problem is now being overcome by new generation of PET/CT scanners that offer volumetric CT capability</p><p>PET appears to be at least as sensitive and specific as CT and MRI in detecting primary head and neck tumors [<a href="#rid53">53,54</a>]. In patients presenting with cervical nodal metastases of unknown origin, the sensitivity of PET for detection of primary tumors is approximately 97 percent [<a href="#rid54">54</a>]. A false negative is most likely seen in small lesions and in primary tumors located at pharyngeal lymphoid tissues with high background physiologic activity.</p><p>PET is superior to both CT and MRI for detecting regional nodal metastases, as well as distant metastases and second primary tumors [<a href="#rid55">55-58</a>]. In a multicenter prospective study, PET imaging alone or in combination with CT improved the TNM staging of primary cancer and altered the management in 13.7 percent of patients [<a href="#rid58">58</a>].</p><p>When used for the initial staging of head and neck cancer, integrated PET/CT imaging appears superior to CT, MRI, or PET alone:</p><p class="bulletIndent1"><span class="glyph">●</span>In one series of 30 patients with newly diagnosed head and neck cancer, PET/CT (98 percent) was better than CT (70 percent) and MR alone (80 percent) in identifying primary tumor invasion of specific anatomical structures. Findings on PET/CT imaging altered management in 7 of 30 patients (23 percent) [<a href="#rid21">21</a>]. Similar findings have been reported by others [<a href="#rid59">59,60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The superiority of PET/CT in evaluating the cervical nodes was shown in a series in which integrated PET/CT was compared with CT alone in 63 patients with newly diagnosed head and neck cancer [<a href="#rid61">61</a>]. While CT alone identified 14 of 17 diseased heminecks (82 percent sensitivity) and 9 of 9 negative heminecks (specificity 100 percent), PET/CT detected metastatic disease in all 17 diseased heminecks and in 26 of 27 nodal zones that were histologically positive at the time of dissection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second report of 68 patients (52 with a squamous cell cancer of the head or neck, 8 with a squamous cell cancer of unknown origin, and 8 with recurrent or metastatic thyroid cancer), six proven malignancies were missed by PET, but only one was missed with PET/CT [<a href="#rid62">62</a>]. Of the 157 foci with abnormal FDG uptake, the fraction of equivocal lesions decreased by 53 percent with the integration of PET and CT (from 39 of 155 with PET to 18 of 157). Findings on PET/CT changed the treatment plan in 12 patients (18 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective report of 123 patients with previously untreated head and neck cancer who underwent pretreatment PET/CT, the scan was true positive in 103 (83 percent), while 15 (12.2 percent) had a false-positive study at the primary or elsewhere [<a href="#rid63">63</a>]. Synchronous lesions were found in 10 patients (8.3 percent) and distant metastases in 19 (15.4 percent). Of the 40 heminecks that underwent dissection, PET was positive in 19 of the 22 involved sides (sensitivity 86 percent) and it was negative in 16 of 17 uninvolved sides (specificity 96 percent). Overall, management was altered in 38 patients (31 percent) as a result of the PET scan. The originally planned surgery was canceled (19 patients, 15 percent) because of metastatic disease or finding a primary tumor residing outside of the head and neck region.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>False negatives of PET may be seen in lymph nodes less than 5 mm, necrotic or cystic lymph nodes, and tumors of low metabolic activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The sensitivity of PET/CT may be lower for patients with a clinically negative (N0) neck, a reflection of its limitations in detecting occult nodal metastases less than 5 mm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One multicenter study of 212 participants sought to determine the negative predictive value of PET/CT for the clinically N0 neck based upon neck dissection pathology [<a href="#rid64">64</a>]. In this study, the negative predictive value of PET/CT in patients with T2 to T4 cancers was 87 percent. Moreover, the neck dissection surgical treatment plan was modified in 22 percent of patients based upon the PET/CT findings.</p><p></p><p>Taken together, these data indicate that PET/CT is accurate for detecting occult cervical nodal metastases, although it does not have the sensitivity to replace neck dissection. Its main utility is in finding occult distant metastases, unknown primary lesions, and synchronous second primary tumors, as well as altering radiation fields and doses for patients who are not undergoing neck dissection. (See <a class="local">'Evaluation for distant metastases'</a> below.)</p><p>Contemporary studies suggest that PET/CT may be beneficial and cost effective for restaging of advanced head and neck cancer [<a href="#rid65">65-67</a>]. Negative PET/CT findings after chemoradiation may accurately determine early disease response, making further surgical intervention unnecessary [<a href="#rid67">67</a>]. In a prospective randomized controlled trial including patients with initial N2 or N3 disease treated initially by chemoradiation, patients undergoing PET/CT surveillance were shown to have similar survival rates compared with those with postchemoradiation neck dissection [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Evaluation for distant metastases</span><span class="headingEndMark"> — </span>A component of the initial staging evaluation for patients with new or recurrent head and neck cancer is the search for distant metastases. The reported incidence is between 2 and 26 percent and varies based on locoregional control, nodal involvement (number and presence of extracapsular extension), primary site (particularly hypopharynx), histologic grade, and T stage [<a href="#rid68">68-71</a>].</p><p>Distant metastases at initial diagnosis are usually asymptomatic; the most common sites are the lungs followed by the liver and bone. Screening tests such as chest radiograph, serum alkaline phosphatase, and liver function tests are insensitive to the presence of distant metastases [<a href="#rid72">72-74</a>].</p><p>CT scan was the most sensitive method to screen for distant metastases in patients with head and neck cancer, identifying malignant findings in between 4 and 19 percent of newly diagnosed cases [<a href="#rid74">74-80</a>]. Although chest CT detects distant metastases more frequently than chest radiograph, it fails to detect the 2 to 5 percent of patients who will have distant metastases outside the chest [<a href="#rid75">75,81,82</a>]. </p><p>PET and integrated PET/CT have greatly replaced other tests for detection of distant metastases and synchronous second primary tumors [<a href="#rid59">59,81-86</a>]. However, false-positive findings are common, underscoring the need to undertake histologic confirmation of any sites of abnormal uptake. PET/CT is sensitive and superior for evaluation of deep lesions, while panendoscopy is highly accurate for evaluation of smaller or more superficial second primary mucosal lesions. PET/CT and direct mucosal inspection therefore play important complimentary roles in the work-up of head and neck cancers. (See <a class="local">'PET and integrated PET/CT'</a> above.)</p><p>These issues can be illustrated by a series of 349 patients with head and neck tumors who underwent preoperative head/neck CT or MRI and whole body PET/CT [<a href="#rid84">84</a>]. Further diagnostic imaging was guided by the results of the PET/CT scan. Overall there were 14 second primary tumors (4 percent) and 26 patients with distant metastases (7.4 percent) detected during staging or within 15 months of surgery. PET/CT correctly identified all but one (a patient with CT-demonstrable metastases in the lungs and gluteus muscle). However, there were 23 false-positive PET/CT results. Overall, the sensitivity, specificity, positive predictive value and negative predictive value were 98, 93, 63, and 99.7 percent, respectively.</p><p class="headingAnchor" id="H19"><span class="h2">Incidence of second and multiple primaries</span><span class="headingEndMark"> — </span>At-risk patients (ie, those with strong tobacco and alcohol use or family history) are prone to develop second primary cancers of the upper aerodigestive tract. Such tumors may be present at presentation or develop subsequently. (See  <a class="medical medical_review" href="/z/d/html/3405.html" rel="external">"Second primary malignancies in patients with head and neck cancers"</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Future molecular staging methods</span><span class="headingEndMark"> — </span>Analyzing differences in gene expression patterns across individual patients with a certain type of cancer may reveal molecular differences that permit refinements in their classification, prognostication, and treatment selection. (See  <a class="medical medical_review" href="/z/d/html/3387.html" rel="external">"Head and neck squamous cell carcinogenesis: Molecular and genetic alterations"</a>.)</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Molecular profiling and DNA genotyping has been shown to predict radiosensitivity and radiotoxicity in patients with head and neck cancer [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>COMT</em> and <em>MATE1</em> genotyping were found to predict cisplatin-induced ototoxicity in 206 head and neck cancer patients [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Circulating tumor DNA (ctDNA) is being used to determine driver mutations, which could subsequently direct targeted molecular therapy. The role of ctDNA is also being investigated to detect disease recurrence as part of posttreatment surveillance, which are discussed separately [<a href="#rid89">89-91</a>]. (See  <a class="medical medical_review" href="/z/d/html/115014.html" rel="external">"Treatment of human papillomavirus associated oropharyngeal cancer", section on 'Surveillance'</a>.)</p><p></p><p class="headingAnchor" id="H2894149782"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/128559.html" rel="external">"Society guideline links: Head and neck cancer"</a>.)</p><p class="headingAnchor" id="H23374466"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16834.html" rel="external">"Patient education: Mouth sores (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/83257.html" rel="external">"Patient education: Tongue cancer (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/83251.html" rel="external">"Patient education: Laryngeal cancer (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/83256.html" rel="external">"Patient education: Throat cancer (The Basics)"</a>) </p><p></p><p class="headingAnchor" id="H6093555"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sites of disease</strong> – Head and neck cancer encompasses a variety of malignancies, mostly squamous cell carcinomas, which can arise from a variety of sites, such as the oral cavity, pharynx, larynx, nasal cavity and paranasal sinuses, or salivary glands  (<a class="graphic graphic_figure graphicRef97306 graphicRef115303" href="/z/d/graphic/97306.html" rel="external">figure 1A-B</a>). (See <a class="local">'Anatomic subsites'</a> above and <a class="local">'Pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – For patients with head and neck cancer, initial symptoms and subsequent staging depend upon the site of the primary tumor. (See <a class="local">'Clinical presentation'</a> above and <a class="local">'TNM staging system'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – Proper staging of the primary tumor, regional lymph nodes, and distant metastases is required to develop an optimal treatment plan. (See <a class="local">'Initial evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Physical exam</strong> – The initial assessment of the primary tumor includes a combination of inspection, palpation, indirect mirror examination, and direct endoscopy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Biopsy</strong> – For patients who present with a neck mass (metastatic cervical lymph node) without an obvious primary mucosal/upper aerodigestive tract site, a fine needle aspiration (FNA) biopsy is frequently used to make an initial tissue diagnosis of a head and neck cancer. (See <a class="local">'Fine needle aspiration biopsy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications for EUA</strong> – Due to improved biopsy techniques, an examination under anesthesia (EUA) is most often performed to obtain a tissue diagnosis, for surgical planning, and to search for carcinoma of unknown primary. EUA may be particularly useful for patients with laryngeal and hypopharyngeal malignancies. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Imaging</strong> – Imaging studies (computed tomography [CT], magnetic resonance imaging [MRI], positron emission tomography [PET], and integrated PET/CT) are important to assess the degree of local infiltration, involvement of regional lymph nodes  (<a class="graphic graphic_figure graphicRef54099" href="/z/d/graphic/54099.html" rel="external">figure 2</a>), and presence of distant metastases or second primary tumors. The evaluation of regional lymph nodes has improved significantly with the development of imaging modalities such as integrated PET/CT, but these approaches still can miss more limited degrees of tumor involvement. (See <a class="local">'Imaging studies'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>CT or MRI of the head and neck</strong> – All patients should have a staging CT scan or MRI of the head and neck (although CT scan of the brain is not needed). (See <a class="local">'CT scan'</a> above and <a class="local">'Magnetic resonance imaging'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Indications for PET/CT</strong> – The role of a routine PET scan in staging of all patients is less clear. PET/CT imaging is indicated for patients at high risk for metastatic disease, in those with equivocal findings on CT or MRI scan, or in those at increased risk of second malignancy (especially those with a smoking history) who are not having an operative panendoscopy (laryngoscopy, esophagoscopy, bronchoscopy). For restaging of head and neck cancer after initial therapy, PET/CT may provide additional benefits. (See <a class="local">'PET and integrated PET/CT'</a> above and <a class="local">'Evaluation for distant metastases'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Patterson RH, Fischman VG, Wasserman I, et al. Global Burden of Head and Neck Cancer: Economic Consequences, Health, and the Role of Surgery. Otolaryngol Head Neck Surg 2020; 162:296.</a></li><li><a class="nounderline abstract_t">Bradley PT, Bradley PJ. Branchial cleft cyst carcinoma: fact or fiction? Curr Opin Otolaryngol Head Neck Surg 2013; 21:118.</a></li><li><a class="nounderline abstract_t">Silverman S Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 1984; 53:563.</a></li><li><a class="nounderline abstract_t">Fakhry C, Lacchetti C, Rooper LM, et al. Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline. J Clin Oncol 2018; 36:3152.</a></li><li><a class="nounderline abstract_t">Lewis JS Jr, Beadle B, Bishop JA, et al. Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists. Arch Pathol Lab Med 2018; 142:559.</a></li><li class="breakAll">Part II Head and Neck. In: AJCC Cancer Staging Manual, 8th ed, Amid MB (Ed), Springer, New York 2017. p.53, corrected at 4th printing, 2018.</li><li><a class="nounderline abstract_t">Noor A, Stepan L, Kao SS, et al. Reviewing indications for panendoscopy in the investigation of head and neck squamous cell carcinoma. J Laryngol Otol 2018; 132:901.</a></li><li><a class="nounderline abstract_t">Golusinski P, Di Maio P, Pehlivan B, et al. Evidence for the approach to the diagnostic evaluation of squamous cell carcinoma occult primary tumors of the head and neck. Oral Oncol 2019; 88:145.</a></li><li><a class="nounderline abstract_t">Rennemo E, Zätterström U, Boysen M. Synchronous second primary tumors in 2,016 head and neck cancer patients: role of symptom-directed panendoscopy. Laryngoscope 2011; 121:304.</a></li><li><a class="nounderline abstract_t">Strobel K, Haerle SK, Stoeckli SJ, et al. Head and neck squamous cell carcinoma (HNSCC)--detection of synchronous primaries with (18)F-FDG-PET/CT. Eur J Nucl Med Mol Imaging 2009; 36:919.</a></li><li><a class="nounderline abstract_t">Hujala K, Sipilä J, Grenman R. Panendoscopy and synchronous second primary tumors in head and neck cancer patients. Eur Arch Otorhinolaryngol 2005; 262:17.</a></li><li><a class="nounderline abstract_t">Rodriguez-Bruno K, Ali MJ, Wang SJ. Role of panendoscopy to identify synchronous second primary malignancies in patients with oral cavity and oropharyngeal squamous cell carcinoma. Head Neck 2011; 33:949.</a></li><li><a class="nounderline abstract_t">Haerle SK, Strobel K, Hany TF, et al. (18)F-FDG-PET/CT versus panendoscopy for the detection of synchronous second primary tumors in patients with head and neck squamous cell carcinoma. Head Neck 2010; 32:319.</a></li><li><a class="nounderline abstract_t">Sokoya M, Chowdhury F, Kadakia S, Ducic Y. Combination of panendoscopy and positron emission tomography/computed tomography increases detection of unknown primary head and neck carcinoma. Laryngoscope 2018; 128:2573.</a></li><li><a class="nounderline abstract_t">Feldman PS, Kaplan MJ, Johns ME, Cantrell RW. Fine-needle aspiration in squamous cell carcinoma of the head and neck. Arch Otolaryngol 1983; 109:735.</a></li><li><a class="nounderline abstract_t">Tandon S, Shahab R, Benton JI, et al. Fine-needle aspiration cytology in a regional head and neck cancer center: comparison with a systematic review and meta-analysis. Head Neck 2008; 30:1246.</a></li><li><a class="nounderline abstract_t">Pisharodi LR. False-negative diagnosis in fine-needle aspirations of squamous-cell carcinoma of head and neck. Diagn Cytopathol 1997; 17:70.</a></li><li><a class="nounderline abstract_t">Righi PD, Kopecky KK, Caldemeyer KS, et al. Comparison of ultrasound-fine needle aspiration and computed tomography in patients undergoing elective neck dissection. Head Neck 1997; 19:604.</a></li><li><a class="nounderline abstract_t">Takes RP, Righi P, Meeuwis CA, et al. The value of ultrasound with ultrasound-guided fine-needle aspiration biopsy compared to computed tomography in the detection of regional metastases in the clinically negative neck. Int J Radiat Oncol Biol Phys 1998; 40:1027.</a></li><li><a class="nounderline abstract_t">Dammann F, Horger M, Mueller-Berg M, et al. Rational diagnosis of squamous cell carcinoma of the head and neck region: comparative evaluation of CT, MRI, and 18FDG PET. AJR Am J Roentgenol 2005; 184:1326.</a></li><li><a class="nounderline abstract_t">Wong WL, Hussain K, Chevretton E, et al. Validation and clinical application of computer-combined computed tomography and positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose head and neck images. Am J Surg 1996; 172:628.</a></li><li><a class="nounderline abstract_t">Atula TS, Varpula MJ, Kurki TJ, et al. Assessment of cervical lymph node status in head and neck cancer patients: palpation, computed tomography and low field magnetic resonance imaging compared with ultrasound-guided fine-needle aspiration cytology. Eur J Radiol 1997; 25:152.</a></li><li><a class="nounderline abstract_t">Alkureishi LW, Ross GL, Shoaib T, et al. Sentinel node biopsy in head and neck squamous cell cancer: 5-year follow-up of a European multicenter trial. Ann Surg Oncol 2010; 17:2459.</a></li><li><a class="nounderline abstract_t">Barzan L, Sulfaro S, Alberti F, et al. An extended use of the sentinel node in head and neck squamous cell carcinoma: results of a prospective study of 100 patients. Acta Otorhinolaryngol Ital 2004; 24:145.</a></li><li><a class="nounderline abstract_t">Stoeckli SJ, Broglie MA. Sentinel node biopsy for early oral carcinoma. Curr Opin Otolaryngol Head Neck Surg 2012; 20:103.</a></li><li><a class="nounderline abstract_t">Thompson CF, St John MA, Lawson G, et al. Diagnostic value of sentinel lymph node biopsy in head and neck cancer: a meta-analysis. Eur Arch Otorhinolaryngol 2013; 270:2115.</a></li><li><a class="nounderline abstract_t">Monroe MM, Lai SY. Sentinel lymph node biopsy for oral cancer: supporting evidence and recent novel developments. Curr Oncol Rep 2014; 16:385.</a></li><li class="breakAll">National Comprehensive Cancer Network Guidelines for Head and Neck Cancer https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (Accessed on March 17, 2021).</li><li><a class="nounderline abstract_t">Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007; 357:2277.</a></li><li><a class="nounderline abstract_t">Zinsser D, Marcus R, Othman AE, et al. Dose Reduction and Dose Management in Computed Tomography - State of the Art. Rofo 2018; 190:531.</a></li><li><a class="nounderline abstract_t">Albert JM. Radiation risk from CT: implications for cancer screening. AJR Am J Roentgenol 2013; 201:W81.</a></li><li><a class="nounderline abstract_t">Weissman JL, Akindele R. Current imaging techniques for head and neck tumors. Oncology (Williston Park) 1999; 13:697.</a></li><li><a class="nounderline abstract_t">Feldhaus F, Böning G, Jonczyk M, et al. Metallic dental artifact reduction in computed tomography (Smart MAR): Improvement of image quality and diagnostic confidence in patients with suspected head and neck pathology and oral implants. Eur J Radiol 2019; 118:153.</a></li><li><a class="nounderline abstract_t">Weissman JL, Carrau RL. "Puffed-cheek" CT improves evaluation of the oral cavity. AJNR Am J Neuroradiol 2001; 22:741.</a></li><li><a class="nounderline abstract_t">Kuno H, Onaya H, Iwata R, et al. Evaluation of cartilage invasion by laryngeal and hypopharyngeal squamous cell carcinoma with dual-energy CT. Radiology 2012; 265:488.</a></li><li><a class="nounderline abstract_t">Kuno H, Onaya H, Fujii S, et al. Primary staging of laryngeal and hypopharyngeal cancer: CT, MR imaging and dual-energy CT. Eur J Radiol 2014; 83:e23.</a></li><li><a class="nounderline abstract_t">Vogl TJ, Schulz B, Bauer RW, et al. Dual-energy CT applications in head and neck imaging. AJR Am J Roentgenol 2012; 199:S34.</a></li><li><a class="nounderline abstract_t">Prehn RB, Pasic TR, Harari PM, et al. Influence of computed tomography on pretherapeutic tumor staging in head and neck cancer patients. Otolaryngol Head Neck Surg 1998; 119:628.</a></li><li><a class="nounderline abstract_t">Anzai Y, Brunberg JA, Lufkin RB. Imaging of nodal metastases in the head and neck. J Magn Reson Imaging 1997; 7:774.</a></li><li><a class="nounderline abstract_t">Curtin HD, Ishwaran H, Mancuso AA, et al. Comparison of CT and MR imaging in staging of neck metastases. Radiology 1998; 207:123.</a></li><li><a class="nounderline abstract_t">Hoang JK, Vanka J, Ludwig BJ, Glastonbury CM. Evaluation of cervical lymph nodes in head and neck cancer with CT and MRI: tips, traps, and a systematic approach. AJR Am J Roentgenol 2013; 200:W17.</a></li><li><a class="nounderline abstract_t">Sun J, Li B, Li CJ, et al. Computed tomography versus magnetic resonance imaging for diagnosing cervical lymph node metastasis of head and neck cancer: a systematic review and meta-analysis. Onco Targets Ther 2015; 8:1291.</a></li><li><a class="nounderline abstract_t">van den Brekel MW, Stel HV, Castelijns JA, et al. Cervical lymph node metastasis: assessment of radiologic criteria. Radiology 1990; 177:379.</a></li><li><a class="nounderline abstract_t">Castelijns JA, van den Brekel MW. Detection of lymph node metastases in the neck: radiologic criteria. AJNR Am J Neuroradiol 2001; 22:3.</a></li><li><a class="nounderline abstract_t">Schwartz LH, Bogaerts J, Ford R, et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer 2009; 45:261.</a></li><li><a class="nounderline abstract_t">Häussinger K, Fruhmann G, Fuchs G. [Occupation medicine-results of a routine examination (author's transl)]. MMW Munch Med Wochenschr 1974; 116:723.</a></li><li><a class="nounderline abstract_t">Merritt RM, Williams MF, James TH, Porubsky ES. Detection of cervical metastasis. A meta-analysis comparing computed tomography with physical examination. Arch Otolaryngol Head Neck Surg 1997; 123:149.</a></li><li><a class="nounderline abstract_t">Don DM, Anzai Y, Lufkin RB, et al. Evaluation of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Laryngoscope 1995; 105:669.</a></li><li><a class="nounderline abstract_t">Sakata K, Hareyama M, Tamakawa M, et al. Prognostic factors of nasopharynx tumors investigated by MR imaging and the value of MR imaging in the newly published TNM staging. Int J Radiat Oncol Biol Phys 1999; 43:273.</a></li><li><a class="nounderline abstract_t">Rasch C, Keus R, Pameijer FA, et al. The potential impact of CT-MRI matching on tumor volume delineation in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1997; 39:841.</a></li><li><a class="nounderline abstract_t">Kuno H, Sakamaki K, Fujii S, et al. Comparison of MR Imaging and Dual-Energy CT for the Evaluation of Cartilage Invasion by Laryngeal and Hypopharyngeal Squamous Cell Carcinoma. AJNR Am J Neuroradiol 2018; 39:524.</a></li><li><a class="nounderline abstract_t">Pfister DG, Spencer S, Adelstein D, et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020; 18:873.</a></li><li><a class="nounderline abstract_t">Rudmik L, Lau HY, Matthews TW, et al. Clinical utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: a prospective clinical trial. Head Neck 2011; 33:935.</a></li><li><a class="nounderline abstract_t">Zhu L, Wang N. 18F-fluorodeoxyglucose positron emission tomography-computed tomography as a diagnostic tool in patients with cervical nodal metastases of unknown primary site: a meta-analysis. Surg Oncol 2013; 22:190.</a></li><li><a class="nounderline abstract_t">Johnson JT, Branstetter BF 4th. PET/CT in head and neck oncology: State-of-the-art 2013. Laryngoscope 2014; 124:913.</a></li><li><a class="nounderline abstract_t">Escott EJ. Role of positron emission tomography/computed tomography (PET/CT) in head and neck cancer. Radiol Clin North Am 2013; 51:881.</a></li><li><a class="nounderline abstract_t">Xu G, Li J, Zuo X, Li C. Comparison of whole body positron emission tomography (PET)/PET-computed tomography and conventional anatomic imaging for detecting distant malignancies in patients with head and neck cancer: a meta-analysis. Laryngoscope 2012; 122:1974.</a></li><li><a class="nounderline abstract_t">Lonneux M, Hamoir M, Reychler H, et al. Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. J Clin Oncol 2010; 28:1190.</a></li><li><a class="nounderline abstract_t">Zanation AM, Sutton DK, Couch ME, et al. Use, accuracy, and implications for patient management of [18F]-2-fluorodeoxyglucose-positron emission/computerized tomography for head and neck tumors. Laryngoscope 2005; 115:1186.</a></li><li><a class="nounderline abstract_t">Ha PK, Hdeib A, Goldenberg D, et al. The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006; 132:12.</a></li><li><a class="nounderline abstract_t">Schwartz DL, Ford E, Rajendran J, et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005; 61:129.</a></li><li><a class="nounderline abstract_t">Schöder H, Yeung HW, Gonen M, et al. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004; 231:65.</a></li><li><a class="nounderline abstract_t">Fleming AJ Jr, Smith SP Jr, Paul CM, et al. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 2007; 117:1173.</a></li><li><a class="nounderline abstract_t">Lowe VJ, Duan F, Subramaniam RM, et al. Multicenter Trial of [18F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results From ACRIN 6685. J Clin Oncol 2019; 37:1704.</a></li><li><a class="nounderline abstract_t">Antoniou AJ, Marcus C, Subramaniam RM. Value of imaging in head and neck tumors. Surg Oncol Clin N Am 2014; 23:685.</a></li><li><a class="nounderline abstract_t">Mehanna H, Wong WL, McConkey CC, et al. PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. N Engl J Med 2016; 374:1444.</a></li><li><a class="nounderline abstract_t">Malone JP, Gerberi MA, Vasireddy S, et al. Early prediction of response to chemoradiotherapy for head and neck cancer: reliability of restaging with combined positron emission tomography and computed tomography. Arch Otolaryngol Head Neck Surg 2009; 135:1119.</a></li><li><a class="nounderline abstract_t">Garavello W, Ciardo A, Spreafico R, Gaini RM. Risk factors for distant metastases in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006; 132:762.</a></li><li><a class="nounderline abstract_t">León X, Quer M, Orús C, et al. Distant metastases in head and neck cancer patients who achieved loco-regional control. Head Neck 2000; 22:680.</a></li><li><a class="nounderline abstract_t">Leibel SA, Scott CB, Mohiuddin M, et al. The effect of local-regional control on distant metastatic dissemination in carcinoma of the head and neck: results of an analysis from the RTOG head and neck database. Int J Radiat Oncol Biol Phys 1991; 21:549.</a></li><li><a class="nounderline abstract_t">Liao CT, Wang HM, Chang JT, et al. Analysis of risk factors for distant metastases in squamous cell carcinoma of the oral cavity. Cancer 2007; 110:1501.</a></li><li><a class="nounderline abstract_t">Troell RJ, Terris DJ. Detection of metastases from head and neck cancers. Laryngoscope 1995; 105:247.</a></li><li><a class="nounderline abstract_t">Korver KD, Graham SM, Hoffman HT, et al. Liver function studies in the assessment of head and neck cancer patients. Head Neck 1995; 17:531.</a></li><li><a class="nounderline abstract_t">Houghton DJ, Hughes ML, Garvey C, et al. Role of chest CT scanning in the management of patients presenting with head and neck cancer. Head Neck 1998; 20:614.</a></li><li><a class="nounderline abstract_t">de Bree R, Deurloo EE, Snow GB, Leemans CR. Screening for distant metastases in patients with head and neck cancer. Laryngoscope 2000; 110:397.</a></li><li><a class="nounderline abstract_t">Loh KS, Brown DH, Baker JT, et al. A rational approach to pulmonary screening in newly diagnosed head and neck cancer. Head Neck 2005; 27:990.</a></li><li><a class="nounderline abstract_t">Reiner B, Siegel E, Sawyer R, et al. The impact of routine CT of the chest on the diagnosis and management of newly diagnosed squamous cell carcinoma of the head and neck. AJR Am J Roentgenol 1997; 169:667.</a></li><li><a class="nounderline abstract_t">Tan L, Greener CC, Seikaly H, et al. Role of screening chest computed tomography in patients with advanced head and neck cancer. Otolaryngol Head Neck Surg 1999; 120:689.</a></li><li><a class="nounderline abstract_t">Ong TK, Kerawala CJ, Martin IC, Stafford FW. The role of thorax imaging in staging head and neck squamous cell carcinoma. J Craniomaxillofac Surg 1999; 27:339.</a></li><li><a class="nounderline abstract_t">Keski-Säntti HT, Markkola AT, Mäkitie AA, et al. CT of the chest and abdomen in patients with newly diagnosed head and neck squamous cell carcinoma. Head Neck 2005; 27:909.</a></li><li><a class="nounderline abstract_t">Brouwer J, de Bree R, Hoekstra OS, et al. Screening for distant metastases in patients with head and neck cancer: is chest computed tomography sufficient? Laryngoscope 2005; 115:1813.</a></li><li><a class="nounderline abstract_t">Brouwer J, Senft A, de Bree R, et al. Screening for distant metastases in patients with head and neck cancer: is there a role for (18)FDG-PET? Oral Oncol 2006; 42:275.</a></li><li><a class="nounderline abstract_t">Schmid DT, Stoeckli SJ, Bandhauer F, et al. Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck. Laryngoscope 2003; 113:888.</a></li><li><a class="nounderline abstract_t">Kim SY, Roh JL, Yeo NK, et al. Combined 18F-fluorodeoxyglucose-positron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in patients with head and neck cancer. Ann Oncol 2007; 18:1698.</a></li><li><a class="nounderline abstract_t">Teknos TN, Rosenthal EL, Lee D, et al. Positron emission tomography in the evaluation of stage III and IV head and neck cancer. Head Neck 2001; 23:1056.</a></li><li><a class="nounderline abstract_t">Basu D, Siegel BA, McDonald DJ, Nussenbaum B. Detection of occult bone metastases from head and neck squamous cell carcinoma: impact of positron emission tomography computed tomography with fluorodeoxyglucose F 18. Arch Otolaryngol Head Neck Surg 2007; 133:801.</a></li><li><a class="nounderline abstract_t">Drobin K, Marczyk M, Halle M, et al. Molecular Profiling for Predictors of Radiosensitivity in Patients with Breast or Head-and-Neck Cancer. Cancers (Basel) 2020; 12.</a></li><li><a class="nounderline abstract_t">Teft WA, Winquist E, Nichols AC, et al. Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients. Oral Oncol 2019; 89:72.</a></li><li><a class="nounderline abstract_t">Egyud M, Sridhar P, Devaiah A, et al. Plasma circulating tumor DNA as a potential tool for disease monitoring in head and neck cancer. Head Neck 2019; 41:1351.</a></li><li><a class="nounderline abstract_t">Payne K, Spruce R, Beggs A, et al. Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma. Head Neck 2018; 40:1598.</a></li><li><a class="nounderline abstract_t">Chera BS, Kumar S, Shen C, et al. Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer. J Clin Oncol 2020; 38:1050.</a></li></ol></div><div id="topicVersionRevision">Topic 3393 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31906785" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Global Burden of Head and Neck Cancer: Economic Consequences, Health, and the Role of Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23328541" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Branchial cleft cyst carcinoma: fact or fiction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6537892" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Oral leukoplakia and malignant transformation. A follow-up study of 257 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30188786" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29251996" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29251996" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30289089" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Reviewing indications for panendoscopy in the investigation of head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30616785" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Evidence for the approach to the diagnostic evaluation of squamous cell carcinoma occult primary tumors of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21271578" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Synchronous second primary tumors in 2,016 head and neck cancer patients: role of symptom-directed panendoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19205699" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Head and neck squamous cell carcinoma (HNSCC)--detection of synchronous primaries with (18)F-FDG-PET/CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15004709" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Panendoscopy and synchronous second primary tumors in head and neck cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21674670" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Role of panendoscopy to identify synchronous second primary malignancies in patients with oral cavity and oropharyngeal squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19626642" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : (18)F-FDG-PET/CT versus panendoscopy for the detection of synchronous second primary tumors in patients with head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30194842" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Combination of panendoscopy and positron emission tomography/computed tomography increases detection of unknown primary head and neck carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6639441" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Fine-needle aspiration in squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18528906" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Fine-needle aspiration cytology in a regional head and neck cancer center: comparison with a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9218909" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : False-negative diagnosis in fine-needle aspirations of squamous-cell carcinoma of head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9323149" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of ultrasound-fine needle aspiration and computed tomography in patients undergoing elective neck dissection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9539556" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The value of ultrasound with ultrasound-guided fine-needle aspiration biopsy compared to computed tomography in the detection of regional metastases in the clinically negative neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15788619" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Rational diagnosis of squamous cell carcinoma of the head and neck region: comparative evaluation of CT, MRI, and 18FDG PET.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8988664" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Validation and clinical application of computer-combined computed tomography and positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose head and neck images.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9283844" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Assessment of cervical lymph node status in head and neck cancer patients: palpation, computed tomography and low field magnetic resonance imaging compared with ultrasound-guided fine-needle aspiration cytology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20552410" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Sentinel node biopsy in head and neck squamous cell cancer: 5-year follow-up of a European multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15584585" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : An extended use of the sentinel node in head and neck squamous cell carcinoma: results of a prospective study of 100 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22202232" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Sentinel node biopsy for early oral carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23263205" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Diagnostic value of sentinel lymph node biopsy in head and neck cancer: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24633882" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Sentinel lymph node biopsy for oral cancer: supporting evidence and recent novel developments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24633882" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Sentinel lymph node biopsy for oral cancer: supporting evidence and recent novel developments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18046031" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Computed tomography--an increasing source of radiation exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29534253" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Dose Reduction and Dose Management in Computed Tomography - State of the Art.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23789701" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Radiation risk from CT: implications for cancer screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10356688" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Current imaging techniques for head and neck tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31439235" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Metallic dental artifact reduction in computed tomography (Smart MAR): Improvement of image quality and diagnostic confidence in patients with suspected head and neck pathology and oral implants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11290490" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : "Puffed-cheek" CT improves evaluation of the oral cavity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22984188" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Evaluation of cartilage invasion by laryngeal and hypopharyngeal squamous cell carcinoma with dual-energy CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24239239" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Primary staging of laryngeal and hypopharyngeal cancer: CT, MR imaging and dual-energy CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23097166" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Dual-energy CT applications in head and neck imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9852538" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Influence of computed tomography on pretherapeutic tumor staging in head and neck cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9307901" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Imaging of nodal metastases in the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9530307" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Comparison of CT and MR imaging in staging of neck metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23255768" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Evaluation of cervical lymph nodes in head and neck cancer with CT and MRI: tips, traps, and a systematic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26089682" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Computed tomography versus magnetic resonance imaging for diagnosing cervical lymph node metastasis of head and neck cancer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2217772" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cervical lymph node metastasis: assessment of radiologic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11158879" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Detection of lymph node metastases in the neck: radiologic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19091550" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Evaluation of lymph nodes with RECIST 1.1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4209637" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : [Occupation medicine-results of a routine examination (author's transl)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9046281" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Detection of cervical metastasis. A meta-analysis comparing computed tomography with physical examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7603268" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Evaluation of cervical lymph node metastases in squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10030249" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prognostic factors of nasopharynx tumors investigated by MR imaging and the value of MR imaging in the newly published TNM staging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9369132" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The potential impact of CT-MRI matching on tumor volume delineation in advanced head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29371253" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Comparison of MR Imaging and Dual-Energy CT for the Evaluation of Cartilage Invasion by Laryngeal and Hypopharyngeal Squamous Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32634781" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21674668" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: a prospective clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23849685" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : 18F-fluorodeoxyglucose positron emission tomography-computed tomography as a diagnostic tool in patients with cervical nodal metastases of unknown primary site: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24515562" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : PET/CT in head and neck oncology: State-of-the-art 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24010911" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Role of positron emission tomography/computed tomography (PET/CT) in head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22753007" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Comparison of whole body positron emission tomography (PET)/PET-computed tomography and conventional anatomic imaging for detecting distant malignancies in patients with head and neck cancer: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20124179" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15995504" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Use, accuracy, and implications for patient management of [18F]-2-fluorodeoxyglucose-positron emission/computerized tomography for head and neck tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16415423" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15629603" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14990824" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17603315" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30768363" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Multicenter Trial of [18F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results From ACRIN 6685.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25246046" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Value of imaging in head and neck tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27007578" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19917925" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Early prediction of response to chemoradiotherapy for head and neck cancer: reliability of restaging with combined positron emission tomography and computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16847186" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Risk factors for distant metastases in head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11002323" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Distant metastases in head and neck cancer patients who achieved loco-regional control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1869453" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The effect of local-regional control on distant metastatic dissemination in carcinoma of the head and neck: results of an analysis from the RTOG head and neck database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17868119" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Analysis of risk factors for distant metastases in squamous cell carcinoma of the oral cavity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7877412" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Detection of metastases from head and neck cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8847212" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Liver function studies in the assessment of head and neck cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9744461" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Role of chest CT scanning in the management of patients presenting with head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10718426" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Screening for distant metastases in patients with head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16136584" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A rational approach to pulmonary screening in newly diagnosed head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9275874" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The impact of routine CT of the chest on the diagnosis and management of newly diagnosed squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10229594" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Role of screening chest computed tomography in patients with advanced head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10870751" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The role of thorax imaging in staging head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16114003" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : CT of the chest and abdomen in patients with newly diagnosed head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16222201" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Screening for distant metastases in patients with head and neck cancer: is chest computed tomography sufficient?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16266820" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Screening for distant metastases in patients with head and neck cancer: is there a role for (18)FDG-PET?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12792328" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17716985" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Combined 18F-fluorodeoxyglucose-positron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in patients with head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11774391" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Positron emission tomography in the evaluation of stage III and IV head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17709620" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Detection of occult bone metastases from head and neck squamous cell carcinoma: impact of positron emission tomography computed tomography with fluorodeoxyglucose F 18.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32235817" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Molecular Profiling for Predictors of Radiosensitivity in Patients with Breast or Head-and-Neck Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30732962" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30554450" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Plasma circulating tumor DNA as a potential tool for disease monitoring in head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29542214" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32017652" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
